Menu
/REGISTER
PPB
Fielding
Montecito
Powershare
Loading...
You are here:  Home  >  Health Care  -  Page 39
Latest

Amgen settles lawsuit, says biosimilar works as well as Herceptin

By   /  Thursday, July 21st, 2016  /  Health Care, Latest news  /  Comments Off on Amgen settles lawsuit, says biosimilar works as well as Herceptin

Amgen settled a lawsuit and released positive news about a breast cancer biosimilar this week. The Thousand Oaks-based biotech giant said July 20 the company reached a settlement stemming from a class action lawsuit involving shareholders who sued the company over shares bought from the company between April 22, 2004 and May 10, 2007. Amgen Read More →

Read More →
Latest

FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

By   /  Tuesday, July 19th, 2016  /  Health Care, Latest news  /  Comments Off on FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →

Read More →
Latest

Goleta’s InTouch Health picks DeVivo to replace Wang as CEO

By   /  Tuesday, July 19th, 2016  /  Health Care, Latest news  /  Comments Off on Goleta’s InTouch Health picks DeVivo to replace Wang as CEO

Goleta-based telemedicine provider InTouch Health appointed Joseph DeVivo as the new CEO to replace former CEO Dr. Yulun Wang, the company announced July 19. DeVivo was most recently the CEO of New York-based AngioDynamics, a publicly traded medical device manufacturer. He has more than 25 years of experience in the health care industry. “InTouch Health Read More →

Read More →
Latest

Cost concerns hold up Cottage-Sansum merger

By   /  Friday, July 15th, 2016  /  Health Care, South Coast, Top Stories, Top Story  /  Comments Off on Cost concerns hold up Cottage-Sansum merger

  It was the biggest celebration in Santa Barbara’s history. The 1889 Grand Carnival at the Lobero Theatre attracted more than 5,000 residents who donated $2,742 — about $73,000 in current dollars — to help build the area’s first hospital. The carnival fundraiser was the brainchild of a group of 50 women who set out Read More →

Read More →
Latest

Amgen wins one, loses one in biosimilar battle

By   /  Friday, July 15th, 2016  /  East Ventura County, Health Care, left, Technology  /  Comments Off on Amgen wins one, loses one in biosimilar battle

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Dubroff: Fork in the road for region’s health care delivery system

By   /  Friday, July 15th, 2016  /  Columns, Health Care, Latest news  /  Comments Off on Dubroff: Fork in the road for region’s health care delivery system

Henry Dubroff

By almost any standard, Cottage Health and Sansum Clinic are two of the most successful nonprofits on the Central Coast. They’ve got deep roots in the community, they’ve carved out vast amounts of market share in their respective fields and they are successful, some might say relentless, fundraisers. But does it make sense for them Read More →

Read More →
Latest

Amgen partnering with Japanese company to develop biosimilars

By   /  Thursday, July 14th, 2016  /  Health Care, Latest news  /  Comments Off on Amgen partnering with Japanese company to develop biosimilars

Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →

Read More →